In contrast to directly inhibiting K-Ras, our study sought to activate K-Ras-linked pathways due to previous findings that the overexpression of tumor-promoting transcription factors such as Oct4 and cMyc in tumor cells and MSCs can generate anti-tumor CM17. Here, KRAS is linked to neoplasm.